IMMUNOLOGY2026™ Conference Recordings For Attendees-Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury

Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury

Video Transcription

Video Summary

Hayam Zarin described GenT’s engineered “tissue Tregs” for treating inflammatory and ischemic injury. Since FOXP3-driven Tregs are essential for immune balance but can become unstable and IL-2–limited in disease, the company uses dual AAV engineering to stabilize FOXP3, enable rapamycin-responsive IL-2 signaling, and add tissue-targeting features such as SC2. These cells show stronger homing, cytokine sequestration, and repair programs than basic Tregs. In mouse models, they improved outcomes in acute lung injury and bleomycin lung injury, reducing inflammation, preserving lung architecture, and limiting fibrosis without impairing bacterial or viral clearance. They also benefited acute kidney injury models, lowering inflammatory markers and preserving kidney function. The talk also covered a second-generation immune-evasive allogeneic platform for chronic diseases, with improved persistence in vivo. Q&A addressed mechanisms, comparability to natural Tregs, dosing, and timing of delivery.

Meta Tag

Date April 17, 2026 1:00 PM - 1:15 PM

Room 104AB

Session Targeting Adaptive Immune Responses against Cancer and Other Pathologies

Speaker Payam Zarin

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

tissue Tregs

FOXP3 stabilization

AAV engineering

acute lung injury

acute kidney injury

immune-evasive allogeneic platform

April 17, 2026 1:00 PM - 1:15 PM

104AB

Targeting Adaptive Immune Responses against Cancer and Other Pathologies

Payam Zarin

Vaccines and Immunotherapy (VAC)

2026